NASDAQ:UTHR - United Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $244.50
  • Forecasted Upside: 2.73 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +2.36 (1.00%)

This chart shows the closing price for UTHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New United Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UTHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTHR

Analyst Price Target is $244.50
▲ +2.73% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $244.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 2.73% upside from the last price of $238.00.

This chart shows the closing price for UTHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in United Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2022Jefferies Financial GroupBoost Price Target$223.00 ➝ $245.00High
5/24/2022JPMorgan Chase & Co.Boost Price Target$225.00 ➝ $238.00High
5/24/2022WedbushBoost Price TargetOutperform$236.00 ➝ $263.00High
5/24/2022Credit Suisse GroupBoost Price TargetOutperform$219.00 ➝ $247.00High
5/24/2022HC WainwrightBoost Price TargetBuy$248.00 ➝ $255.00High
5/5/2022OppenheimerBoost Price Target$275.00 ➝ $300.00Low
4/19/2022JPMorgan Chase & Co.Lower Price TargetOverweight$230.00 ➝ $223.00High
2/27/2022WedbushReiterated RatingBuy$276.00 ➝ $236.00Medium
2/25/2022HC WainwrightReiterated RatingBuyMedium
2/25/2022LADENBURG THALM/SH SHLower Price TargetBuy$231.00 ➝ $203.00Low
2/11/2022BTIG ResearchInitiated CoverageNeutralLow
7/14/2021ArgusUpgradeHold ➝ Buy$205.00Low
5/6/2021HC WainwrightBoost Price TargetBuy$195.00 ➝ $248.00High
4/8/2021JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$185.00 ➝ $212.00High
2/25/2021WedbushBoost Price TargetOutperform$255.00 ➝ $260.00Low
2/22/2021Credit Suisse GroupBoost Price TargetOutperform$169.00 ➝ $196.00Low
2/16/2021OppenheimerBoost Price TargetOutperform$200.00 ➝ $275.00Low
2/1/2021HC WainwrightUpgradeNeutral ➝ Buy$125.00 ➝ $195.00Low
1/20/2021OppenheimerBoost Price TargetOutperform$175.00 ➝ $200.00Low
1/20/2021CowenBoost Price TargetOutperform$160.00 ➝ $200.00Low
1/20/2021LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$151.00 ➝ $199.00Low
10/29/2020WedbushBoost Price TargetOutperform$247.00 ➝ $255.00Low
10/29/2020OppenheimerBoost Price TargetOutperform$165.00 ➝ $175.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
7/30/2020OppenheimerBoost Price TargetOutperform$155.00 ➝ $165.00Low
7/29/2020WedbushReiterated RatingBuy$243.00 ➝ $244.00Low
6/25/2020WedbushReiterated RatingBuy$243.00High
6/25/2020Credit Suisse GroupBoost Price TargetOutperform$129.00 ➝ $145.00Medium
6/25/2020HC WainwrightBoost Price TargetNeutral$85.00 ➝ $125.00Medium
6/24/2020OppenheimerInitiated CoverageBuy$155.00Medium
6/17/2020WedbushReiterated RatingBuy$243.00High
6/12/2020CowenReiterated RatingBuy$145.00Medium
4/30/2020WedbushReiterated RatingBuy$243.00Low
4/30/2020Credit Suisse GroupReiterated RatingBuyLow
3/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$115.00 ➝ $123.00High
3/4/2020WedbushReiterated RatingBuy$243.00Low
2/27/2020CowenUpgradeMarket Perform ➝ Outperform$119.00 ➝ $145.00High
2/24/2020WedbushReiterated RatingOutperform ➝ Buy$237.00 ➝ $243.00High
2/13/2020Credit Suisse GroupBoost Price TargetOutperform$113.00 ➝ $121.00Low
2/3/2020WedbushReiterated RatingBuy$237.00Low
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00 ➝ $120.00Low
1/27/2020WedbushReiterated RatingBuy$237.00High
12/15/2019WedbushReiterated RatingBuy$237.00Medium
12/10/2019Credit Suisse GroupReiterated RatingBuy$113.00Low
12/3/2019Bank of AmericaInitiated CoverageUnderperform$80.00High
11/1/2019HC WainwrightReiterated RatingHold$85.00Low
9/13/2019CowenSet Price TargetHold$118.00Low
8/1/2019WedbushReiterated RatingBuy$273.00Low
8/1/2019LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$103.00 ➝ $106.00High
8/1/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold$90.00High
7/1/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$98.00 ➝ $101.00High
5/17/2019UBS GroupUpgradeSell ➝ Neutral$115.00 ➝ $94.00Medium
5/9/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral$98.00Medium
5/8/2019WedbushSet Price TargetBuy$273.00Medium
5/2/2019WedbushBoost Price TargetOutperform ➝ Outperform$269.00 ➝ $273.00High
5/1/2019CowenReiterated RatingHold$103.00High
4/9/2019OppenheimerLower Price TargetOutperform$160.00 ➝ $155.00Low
4/8/2019WedbushSet Price TargetBuy$269.00High
3/26/2019OppenheimerSet Price TargetBuy$160.00Low
3/26/2019Credit Suisse GroupReiterated RatingUnderperform$105.00 ➝ $98.00Medium
3/19/2019OppenheimerReiterated RatingBuyMedium
3/1/2019BarclaysLower Price TargetUnderweight ➝ Underweight$100.00 ➝ $95.00Low
2/28/2019LADENBURG THALM/SH SHSet Price TargetHold$124.00Low
2/27/2019CowenReiterated RatingHold$109.00Low
11/20/2018OppenheimerSet Price TargetBuy$160.00Low
11/19/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Sell$103.00 ➝ $105.00Medium
11/15/2018CowenSet Price TargetHold$106.00High
11/2/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$118.00 ➝ $126.00Low
11/1/2018Credit Suisse GroupLower Price TargetUnderperform ➝ Underperform$106.00 ➝ $103.00Low
11/1/2018HC WainwrightReiterated RatingHold$95.00High
10/31/2018CowenSet Price TargetHold$106.00High
10/12/2018Standpoint ResearchUpgradeHold ➝ BuyLow
9/27/2018WedbushSet Price TargetBuy$253.00High
9/4/2018WedbushSet Price TargetBuy$253.00High
8/13/2018HC WainwrightSet Price TargetHold$95.00Medium
8/8/2018WedbushSet Price TargetBuy$253.00Low
8/8/2018Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
8/2/2018CowenReiterated RatingHold$110.00Medium
8/2/2018BarclaysReiterated RatingSell$100.00High
8/2/2018HC WainwrightReiterated RatingHold$95.00High
8/2/2018WedbushBoost Price TargetOutperform ➝ Outperform$234.00 ➝ $253.00High
7/10/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$104.00 ➝ $107.00Medium
5/3/2018BarclaysLower Price TargetUnderweight ➝ Underweight$105.00 ➝ $95.00Medium
5/3/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$108.00 ➝ $104.00Medium
4/3/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$115.00High
2/22/2018BarclaysReiterated RatingUnderweight ➝ Underweight$115.00 ➝ $105.00Low
2/22/2018Credit Suisse GroupReiterated RatingUnderperform ➝ Underperform$120.00 ➝ $115.00Medium
1/18/2018Credit Suisse GroupReiterated RatingUnderperform ➝ Underperform$118.00Low
1/5/2018OppenheimerBoost Price TargetOutperform$180.00Low
12/27/2017WedbushReiterated RatingOutperform ➝ Outperform$213.00 ➝ $232.00Medium
10/27/2017CowenReiterated RatingHold$129.00N/A
10/26/2017HC WainwrightReiterated RatingHold$95.00N/A
9/8/2017OppenheimerReiterated RatingBuyLow
7/14/2017Jefferies Financial GroupReiterated RatingSell$105.00Low
7/6/2017UBS GroupReiterated RatingSell$106.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $238.00
Low: $232.87
High: $239.09

50 Day Range

MA: $210.78
Low: $174.81
High: $241.14

52 Week Range

Now: $238.00
Low: $158.38
High: $243.30


11,865 shs

Average Volume

475,970 shs

Market Capitalization

$10.78 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: Argus, BTIG Research, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., LADENBURG THALM/SH SH, Oppenheimer Holdings Inc.,, and Wedbush.
View the latest analyst ratings for UTHR.

What is the current price target for United Therapeutics?

0 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $244.50, suggesting a possible upside of 2.7%.
View the latest price targets for UTHR.

What is the current consensus analyst rating for United Therapeutics?

United Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UTHR will outperform the market and that investors should add to their positions of United Therapeutics.
View the latest ratings for UTHR.

How do I contact United Therapeutics' investor relations team?

United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is (301) 608-9292 and its investor relations email address is [email protected] The official website for United Therapeutics is Learn More about contacing United Therapeutics investor relations.